Severe feed restriction increases permeability of mammary gland cell tight junctions and reduces ethanol stability of milk.

201

Search for direct production of charginos and neutralinos in events with three leptons and missing transverse momentum in √s = 7 TeV pp collisions with the ATLAS detector

A search for the direct production of charginos and neutralinos in final states with three electrons or muons and missing transverse momentum is presented. The analysis is based on 4.7 fb−1 of proton–proton collision data delivered by the Large Hadron Collider and recorded with the ATLAS detector. Observations are consistent with Standard Model expectations in three signal regions that are either depleted or enriched in Z-boson decays. Upper limits at 95% confidence level are set in R-parity conserving phenomenological minimal supersymmetric models and in simplified models, significantly extending previous results

Diagnosis And Treatment Of Congenital Hemophilia With Inhibitors. A Latin American Perspective

The Committee of Latin America on the Therapeutics of Inhibitor Groups (CLOTTING) is composed of a number of hemophilia specialists from Latin America. The group aims to encourage the adoption of a good standard of care for Latin American patients with hemophilia. The occurrence of inhibitors in patients with hemophilia poses clinical challenges, and it is estimated that between 1 000 and 3 000 patients in Latin America are affected by hemophilia with inhibitors. There is an urgent need to establish a regional consensus and clinical guidelines for the diagnosis and treatment of these patients. We present an extensive review based on best current clinical practice and published literature, as seen from a Latin American perspective, taking into account the variable nature of hemophilia care available in the various countries in this Region.683227242Ehrenforth, S., Kreuz, W., Scharrer, I., Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs (1992) Lancet, 339, pp. 594-598Katz, J., Prevalence of factor IX inhibitors among patients with haemophilia B: Results of a large-scale North American study (1996) Haemophilia, 2, pp. 28-31Goudemand, J., Pharmaco-economic aspects of inhibitor treatment (1998) Eur J Haematol, 61, pp. 24-27World Hemophilia Federation Report on Global Survey 2006. World Federation of Hemophilia, 2007. On www.wfh.orgconsulted on 23/04/2008Rieger, A., Roisenberg, I., Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil (1999) Thromb Haemost, 81, pp. 475-476Fontes, E.M., Amorim, L., Carvalho, S.M., Farah, M.B., Hemophilia care in the state of Rio de Janeiro, Brazil (2003) Rev Panam Salud Pública, 13, pp. 124-128Izquierdo-Ramírez, J., Contreras-Mulato, E.L., Sotelo-Ham, E.I., Incidence of inhibitors in children with hemophilia A (1988) Bol Med Hosp Infant Méx, 45, pp. 578-582Boadas, A., Ruiz-Sáez, A., Arguello, A., de Bosch, N., Prevalence and acute bleeding treatment of allo and auto FVIII and FIX antibodies cases in Venezuela (2004) Haemophilia, 10, p. 56Wight, J., Paisley, S., The epidemiology of inhibitors in hemophilia A: A systematic review (2003) Haemophilia, 9, pp. 418-435Delivery of treatment for hemophilia (2002) Report of a joint WHO/WFH/ISTH meeting, , World Health OrganizationHay, C.R., Brown, S., Collins, P.W., Keeling, D.M., Liesner, R., The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors Organization (2006) Br J Haematol, 133, pp. 591-605Ewing, N.P., Kasper, C.K., In vitro detection of mild inhibitors to factor VIII in hemophilia (1982) Am J Clin Pathol, 77, pp. 749-752Verbruggen, B., Novakova, I., Wessels, H., Boezeman, J., van den Berg, M., Mauser-Bunschoten, E., The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability (1995) Thromb Haemost, 73, pp. 247-251Giles, A.R., Verbruggen, B., Rivard, G.E., Teitel, J., Walker, I., A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the hemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis (1998) Thromb Haemost, 79, pp. 872-875Verbruggen, B., van Heerde, W., Novakova, I., Lillicrap, D., Giles, A., A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay (2002) Thromb Haemost, 88, pp. 362-364White II, G.C., Rosendaal, F., Aledort, L.M., Lusher, J.M., Rothschild, C., Ingerslev, J., Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis (2001) Thromb Haemost, 85, p. 560Kitchen, S., McCraw, A., (2000) Diagnosis of hemophilia and other bleeding disorders, , A laboratory manual. World Federation of Hemophiliahttp://www.med.unc.edu/isth, Available at:, Accessed November 2005http://www.wfh.org, Available at:, Accessed November 2005Oldenburg, J., Brackmann, H.H., Schwaab, R., Risk factors for inhibitor development in hemophilia A (2000) Haematologica, 85, pp. 7-13Rossetti, L.C., Candela, M., Pérez Bianco, R., de Tezanos Pinto, M., Western, A., Goodeve, A., Analysis of factor VIII gene intron 1 inversion in Argentinean families with severe hemophilia A and a review of the literature (2004) Blood Coagul Fibrinolysis, 15, pp. 569-572Santos, A., Montalva, O., Thomas, S., Veiga, M., De Paula, E., Ozelo, M., Genetic and ethnic aspects related to the development of inhibitors among Brazilian patients with hemophilia from five distinct geographical regions in Brazil (2006) Haemophilia, 12, pp. 1-154Mantilla-Capacho, J.M., Beltrán-Miranda, C.P., Luna-Záizar, H., Frequency of intron 1 and 22 inversions of Factor VIII gene in Mexican patients with severe Hemophilia A (2007) Am J Hematol, 82, pp. 283-287Guidelines for the management of hemophilia. World Federation of Hemophilia, 2005Girolami, A., Luzzatto, G., Varvarikis, C., Pellati, D., Sartori, R., Girolami, B., Main clinical manifestations of a bleeding diathesis: An often disregarded aspect of medical and surgical history taking (2005) Haemophilia, 11, pp. 193-202Suggestions for the management of FVIII inhibitors (2000) Treatment of Hemophilia Monograph, , Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada, revised edition, World Federation of HemophiliaKasper, C., Diagnosis and management of inhibitors to factors VIII and IX (2004) Treatment of Hemophilia Monograph, , World Federation of HemophiliaGringeri, A., Mannucci, P.M., Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with hemophilia and inhibitors (2005) Haemophilia, 11, pp. 611-619Key, N.S., Aledort, L.M., Beardsley, D., Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors (1998) Thromb Haemost, 80, pp. 912-918Ingerslev, J., Sneppen, O., Hvid, I., Fredberg, U., Kristensen, H.L., Sindet-Petersen, S., Treatment of acute bleeding episodes with rFVIIa (1999) Vox Sang, 77, pp. 42-46Santagostino, E., Gringeri, A., Mannucci, P.M., Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention (1999) Br J Haematol, 104, pp. 22-26Negrier, C., Goudemand, J., Sultan, Y., Bertrand, M., Rothschild, C., Lauroua, P., Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity (1997) Thromb Haemost, 77, pp. 1113-1119Astermark, J., Donfield, S.M., DiMichelle, D.M., A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor - The Feiba® NovoSeven® Comparative Study (FENOC) (2007) Blood, 109, pp. 546-551Young, G., Shafer, F.E., Rojas, P., Seremetis, S., Single 270 μg kg-1 dose rFVIIa vs. standard 90 μg kg-1 dose rFVIIa and APCC for home treatment of joint bleeds in hemophilia patients with inhibitors: A randomized comparison (2008) Haemophilia, 14, pp. 287-294Ozelo, M.C., Villaça, P.R., De Almeida, J.O., A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with hemophilia and inhibitors in Brazil (2007) Haemophilia, 13, pp. 462-469Kenet, G., Lubetsky, A., Luboshitz, J., Martinowitz, U., A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven) (2003) J Thromb Haemost, 1, pp. 450-455Parameswaran, R., Shapiro, A.D., Gill, J.C., Kessler, C.M., Dose effect and efficacy of rFVIIa in the treatment of hemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry (2005) Haemophilia, 11, pp. 100-106Kavakli, K., Makris, M., Zulfikar, B., Erhardtsen, E., Abrams, Z.S., Kenet, G., Home treatment of haemarthroses using single dose regimen of recombinant activated factor VII in patients with hemophilia and inhibitors. A multi-centre, randomized, double blind, cross-over trial (2006) Thromb Haemost, 95, pp. 600-605Santagostino, E., Mancuso, M.E., Rocino, A., Mancuso, G., Scaraggi, F., Mannucci, P.M., A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of haemarthroses in hemophiliacs with inhibitors (2006) J Thromb Haemost, 4, pp. 367-371Schneiderman, J., Nugent, D.J., Young, G., Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe hemophilia and inhibitors (2004) Haemophilia, 10, pp. 347-351Lusher, J.M., Shapiro, S.S., Palascak, J.E., Rao, A.V., Levine, P.H., Blatt, P.M., Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: A multicenter therapeutic trial (1980) NEJM, 303, pp. 421-425Teitel, J., Berntorp, E., Collins, P., A systematic approach to controlling problem bleeds in patients with severe congenital hemophilia A and high-titre inhibitors (2007) Haemophilia, 13, pp. 256-263Lloyd Jones, M., Wight, J., Paisley, S., Knight, C., Control of bleeding in patients with hemophilia A with inhibitors: A systematic review (2003) Haemophilia, 9, pp. 464-520Ewenstein, B.M., Takemoto, C., Warrier, I., Nephrotic syndrome as a complication of immune tolerance in hemophilia B (1997) Blood, 89, pp. 1115-1116Warrier, I., Lenk, H., Saidi, P., Pollmann, H., Tengborn, L., Berntorp, E., Nephrotic syndrome in hemophilia B patients with inhibitors (1998) Haemophilia, 4, p. 248Warrier, I., Management of hemophilia B patients with inhibitors and anaphylaxis (1998) Haemophilia, 4, pp. 574-576Strawczynski, H., Stachewitsch, A., Morgenstern, G., Shaw, M.E., Delivery of care to hemophilic children: Home care versus hospitalization (1973) Pediatrics, 51, pp. 986-991Rabiner, S.F., Telfer, M.C., Fajardo, R., Home transfusions of hemophiliacs (1972) JAMA, 221, pp. 885-887Levine, P., The home therapy program at the New England area hemophilia center (1977) Scand J Haematol, 31, pp. 37-51Soucie, J.M., Symons, J.I., Evatt, B., Brettler, D., Huszti, H., Linden, J., Home-based factor infusion therapy and hospitalization for bleeding complications among males with hemophilia (2001) Haemophilia, 7, pp. 198-206Solovieva, S., Clinical severity of disease, functional disability and health-related quality of life. Three-year follow-up study of 150 Finnish patients with coagulation disorders (2001) Haemophilia, 7, pp. 53-63Teitel, J.M., Barnard, D., Israels, S., Lillicrap, D., Poon, M.C., Sek, J., Home management of hemophilia (2004) Haemophilia, 10, pp. 118-133Ingerslev, J., Thykjær, H., Scheibel, E., Approaches towards successful home treatment in patients with inhibitors (1998) Eur J Haematol, 61, pp. 11-14Young, G., McDaniel, M., Nugent, D.J., Prophylactic recombinant factor VIIa in hemophilia patients with inhibitors (2005) Haemophilia, 11, pp. 203-207Saxon, B.R., Shanks, D., Jory, C.B., Williams, V., Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint (2001) Thromb Haemost, 86, pp. 1126-1127Konkle, B.A., Ebbesen, L.S., Erhardtsen, E., Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors (2007) J Thromb Haemost, 5, pp. 1904-1913Hoots, W.K., Ebbesen, L.S., Konkle, B.A., Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of hemophilia patients with inhibitors (2008) Haemophilia, 14, pp. 466-475Leissinger, C.A., Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction (2004) Am J Hematol, 77, pp. 187-193Luu, H., Ewenstein, B., FEIBA safety profile in multiple modes of clinical and home-therapy application (2004) Haemophilia, 10, pp. 10-16Leissinger, C.A., Becton, D.L., Ewing, N.P., Valentino, L.A., Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with hemophilia A and inhibitors (2007) Haemophilia, 13, pp. 249-255Villar, A., Aronis, S., Morfini, M., Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven®) in children vs. adults with hemophilia A (2004) Haemophilia, 10, pp. 352-359Klitgaard, T., Nielsen, T.G., Overview of the human pharmacokinetics of recombinant activated factor VII (2008) Br J Clin Pharmacol, 65, pp. 3-11Rodriguez-Merchan, E.C., Rocino, A., Ewenstein, B., Consensus perspectives on surgery in hemophilia patients with inhibitors: Summary statement (2004) Haemophilia, 10, pp. 50-52Hilgartner, M.W., Factor replacement therapy (1989) Hemophilia in the Child and Adults, pp. 1-26. , Hilgartner MW, Pochedly C eds, New York, Raven Press Ltd(2000) Oxford Textbook of Surgery, , Morris PJ, Wood WG eds, 2nd edition. Oxford, Oxford University PressRickard, K.A., Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in hemophilia (1995) Haemophilia, 1, pp. 8-13Shapiro, A., Gilchrist, G.S., Hoots, W.K., Cooper, H.A., Gastineau, D.A., Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in hemophilia patients with inhibitors undergoing surgery (1998) Thromb Haemost, 80, pp. 773-778Hvid, I., Rodriguez-Merchan, E.C., Orthopaedic surgery in haemophilic patients with inhibitors: An overview (2002) Haemophilia, 8, pp. 288-291Rodriguez-Merchan, E.C., Rocino, A., Literature review of surgery management in inhibitor patients (2004) Haemophilia, 10, pp. 22-29Abshire, T., Kenet, G., Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors (2004) J Thromb Haemost, 2, pp. 899-909Ingerslev, J., Efficacy and safety of Recombinant Factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors (2000) Semin Thromb Hemost, 26, pp. 425-432Tjønnfjord, G.E., Brinch, L., Gedde-Dahl III, T., Brosstad, F.R., Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX (2004) Haemophilia, 10, pp. 174-178Ingerslev, J., Sorensen, B., Role of recombinant activated factor VII as hemostatic support in orthopedic surgery (2006) TATM, 8, pp. 35-42Obergfell, A., Auvinen, M.K., Mathew, P., Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: A review of the literature (2008) Haemophilia, 14, pp. 233-241Ewenstein, B.M., Valentino, L.A., Journeycake, J.M., Consensus recommendations for use of central venous access devices in hemophilia (2004) Haemophilia, 10, pp. 629-648Morado, M., Jimenez-Yuste, V., Villar, A., Complications of central venous catheters in patients with hemophilia and inhibitors (2001) Haemophilia, 7, pp. 551-556Bollard, C.M., Teague, L.R., Berry, E.W., Ockelford, P.A., The use of central venous catheters (portacaths) in children with hemophilia (2000) Haemophilia, 6, pp. 66-70O'Connell, N., Mc Mahon, C., Smith, J., Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with hemophilia and high responding inhibitors (2002) Br J Haematol, 116, pp. 632-635Cooper, H.A., Jones, C.P., Campion, E., Roberts, H.R., Hedner, U., Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with hemophilia B during major orthopaedic procedures (2001) Haemophilia, 7, pp. 517-522Colowick, A.B., Bohn, R.L., Avorn, J., Ewenstein, B.M., Immune tolerance induction in hemophilia patients with inhibitors: Costly can be cheaper (2000) Blood, 96, pp. 1698-1702Brackmann, H.H., Gormsen, J., Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder (1977) Lancet, 2, p. 933Key, N.S., Inhibitors in congenital coagulation disorders (2004) Br J Haematol, 127, pp. 379-391Nilsson, I.M., Berntorp, E., Zettervall, O., Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII (1988) NEJM, 318, pp. 947-950Mathias, M., Khair, K., Hann, I., Liesner, R., Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe hemophilia (2004) Br J Haematol, 125, pp. 366-368Stasi, R., Brunetti, M., Stipa, E., Amadori, S., Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia (2004) Blood, 103, pp. 4424-4428Carcao, M., Ungar, W.J., Feldman, B.M., Cost-utility analysis in evaluating prophylaxis in hemophilia (2004) Haemophilia, 10, pp. 50-57Curtin, J., Misra, A., Teo, J., Webster, B., Lammi, A., Use of Rituximab as an alternative strategy for the management of difficult high titre inhibitors in children with hemophilia A (2004) Haemophilia, 10, p. 57DiMichele, D., Immune tolerance therapy dose as an outcome predictor (2003) Haemophilia, 9, pp. 382-386Mariani, G., Kroner, B., Immune tolerance in hemophilia with factor VIII inhibitors: Predictors of success (2001) Haematologica, 86, pp. 1186-1193DiMichele, D., Inhibitors: Resolving diagnostic and therapeutic dilemmas (2002) Haemophilia, 8, pp. 280-287Lenk, H., The German Registry of immune tolerance treatment in hemophilia-1999 update (2000) Haematologica, 85, pp. 45-47Haya, S., Lopez, M.F., Aznar, J.A., Batlle, J., Immune tolerance treatment in hemophilia patients with inhibitors: The Spanish Registry (2001) Haemophilia, 7, pp. 154-159DiMichele, D.M., Hoots, W.K., Pipe, S.W., Rivard, G.E., Santagostino, E., International workshop on immune tolerance induction: Consensus recomendations (2007) Haemophilia, 13, pp. 1-22Kreuz, W., Mentzer, D., Auerswald, G., Becker, S., Joseph-Steiner, J., Successful immune tolerance therapy of FVIII inhibitor in children after changing from high to intermediate purity FVIII concentrate (1996) Haemophilia, 2, p. 19Rocino, A., Papa, M.L., Salerno, E., Capasso, F., Miraglia, E., de Biasi, R., Immune tolerance induction in hemophilia A patients with high-responding inhibitors to factor VIII: Experience at a single institution (2001) Haemophilia, 7, pp. 33-38DiMichele, D., Rivard, G., Hay, C., Antunes, S., Inhibitors in hemophilia: Clinical aspects (2004) Haemophilia, 10, pp. 140-145Mauser-Bunschoten, E.P., Nieuwenhuis, H.K., Roosendaal, G., van den Berg, H.M., Low-dose immune tolerance induction in hemophilia A patients with inhibitors (1995) Blood, 86, pp. 983-988Almeida, J., Paula, J.C., Toscano, R., Immune tolerance such as salvage therapy in severe hemophilia A patient with ultra high-responders inhibitors (2002) Haemophilia, 8, p. 538Solano, M.H., Ramírez, C., Parra, L., Tratamiento de inhibidores del factor VIII en hemofilia. (1998) Acta Med Colomb, 23, p. 193Carneiro, J.D.A., Bassit, R.P., Villaça, P.R., Sandoval, E.P.N., Silva, C.S.S.S., D'amico, E.A., Low-dose immune tolerance induction in hemophilia A children with inhibitors (2002) Haemophilia, 8, pp. 538-539Wight, J., Paisley, S., Knight, C., Immune tolerance induction in patients with hemophilia A with inhibitors: A systematic review (2003) Haemophilia, 9, pp. 436-463Tengborg, L., Hansson, S., Fasth, A., Lübeck, P.O., Berg, A., Ljung, R., Anaphylactoid reactions and nephrotic syndrome - a considerable risk during factor IX treatment in patients with hemophilia B and inhibitors: A report on the outcome in two brothers (1998) Haemophilia, 4, pp. 854-859Schulman, S., Safety, efficacy and lessons from continuous infusion with rFVIIa (1998) Haemophilia, 4, pp. 564-567Schulman, S., Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: Safety, monitoring, and cost effectiveness (2000) Semin Thromb Hemost, 26, pp. 421-424Pruthi, R.K., Mathew, P., Valentino, L.A., Sumner, M.J., Seremetis, S., Hoots, W.K., Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in hemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial (2007) Thromb Haemost, 98, pp. 726-732Smith, M.P., Ludlam, C.A., Collins, P.W., Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: Plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding (2001) Thromb Haemost, 86, pp. 949-953Santagostino, E., Morfini, M., Rocino, A., Baudo, F., Scaraggi, F.A., Gringeri, A., Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors (2001) Thromb Haemost, 86, pp. 954-958Mauser-Bunschoten, E.P., Koopman, M.M., Goede-Bolder, A.D., Efficacy of recombinant factor VIIa administered by continuous infusion to hemophilia patients with inhibitors (2002) Haemophilia, 8, pp. 649-656Ludlam, C.A., Smith, M.P., Morfini, M., Gringeri, A., Santagostino, E., Savidge, G.F., A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: A pharmacokinetic and efficacy evaluation (2003) Br J Haematol, 120, pp. 808-813Escobar, M.A., Recombinant Factor VIIa: The possibilities for monitoring (2003) TATM, 5, pp. 51-54Young, G., Ebbesen, L.S., Viuff, D., Evaluation of thromboelastography for monitoring recombinant activated factor VII ex

Measurement of the correlation between flow harmonics of different order in lead-lead collisions at √sNN = 2.76 TeV with the ATLAS detector

Correlations between the elliptic or triangular flow coefficients vm (m=2 or 3) and other flow harmonics vn (n=2 to 5) are measured using √sNN=2.76 TeV Pb+Pb collision data collected in 2010 by the ATLAS experiment at the LHC, corresponding to an integrated luminosity of 7 μb−1. The vm−vn correlations are measured in midrapidity as a function of centrality, and, for events within the same centrality interval, as a function of event ellipticity or triangularity defined in a forward rapidity region. For events within the same centrality interval, v3 is found to be anticorrelated with v2 and this anticorrelation is consistent with similar anticorrelations between the corresponding eccentricities, ε2 and ε3. However, it is observed that v4 increases strongly with v2, and v5 increases strongly with both v2 and v3. The trend and strength of the vm−vn correlations for n=4 and 5 are found to disagree with εm−εn correlations predicted by initial-geometry models. Instead, these correlations are found to be consistent with the combined effects of a linear contribution to vn and a nonlinear term that is a function of v22 or of v2v3, as predicted by hydrodynamic models. A simple two-component fit is used to separate these two contributions. The extracted linear and nonlinear contributions to v4 and v5 are found to be consistent with previously measured event-plane correlations

Search for W′→tb→qqbb decays in pp collisions at √s=8 TeV with the ATLAS detector

A search for a massive W′ gauge boson decaying to a top quark and a bottom quark is performed with the ATLAS detector in pp collisions at the LHC. The dataset was taken at a centre-of-mass energy of √s=8 TeV and corresponds to 20.3 fb−1 of integrated luminosity. This analysis is done in the hadronic decay mode of the top quark, where novel jet substructure techniques are used to identify jets from high-momentum top quarks. This allows for a search for high-mass W′ bosons in the range 1.5–3.0 TeV. b-tagging is used to identify jets originating from b-quarks. The data are consistent with Standard Model background-only expectations, and upper limits at 95 % confidence level are set on the W′→tb cross section times branching ratio ranging from 0.16pb to 0.33pb for left-handed W′ bosons, and ranging from 0.10pb to 0.21pb for W′ bosons with purely right-handed couplings. Upper limits at 95 % confidence level are set on the W′-boson coupling to tb as a function of the W′ mass using an effective field theory approach, which is independent of details of particular models predicting a W′boson

Measurement of the cross section for isolated-photon plus jet production in pp collisions at √s=13 TeV using the ATLAS detector

The dynamics of isolated-photon production in association with a jet in proton–proton collisions at a centre-of-mass energy of 13 TeV are studied with the ATLAS detector at the LHC using a dataset with an integrated luminosity of 3.2 fb−1. Photons are required to have transverse energies above 125 GeV. Jets are identified using the anti- algorithm with radius parameter and required to have transverse momenta above 100 GeV. Measurements of isolated-photon plus jet cross sections are presented as functions of the leading-photon transverse energy, the leading-jet transverse momentum, the azimuthal angular separation between the photon and the jet, the photon–jet invariant mass and the scattering angle in the photon–jet centre-of-mass system. Tree-level plus parton-shower predictions from Sherpa and Pythia as well as next-to-leading-order QCD predictions from Jetphox and Sherpa are compared to the measurements

Search for vectorlike B quarks in events with one isolated lepton, missing transverse momentum, and jets at √s = 8 TeV with the ATLAS detector

A search has been performed for pair production of heavy vectorlike down-type (B) quarks. The analysis explores the lepton-plus-jets final state, characterized by events with one isolated charged lepton (electron or muon), significant missing transverse momentum, and multiple jets. One or more jets are required to be tagged as arising from b quarks, and at least one pair of jets must be tagged as arising from the hadronic decay of an electroweak boson. The analysis uses the full data sample of pp collisions recorded in 2012 by the ATLAS detector at the LHC, operating at a center-of-mass energy of 8 TeV, corresponding to an integrated luminosity of 20.3 fb −1 . No significant excess of events is observed above the expected background. Limits are set on vectorlike B production, as a function of the B branching ratios, assuming the allowable decay modes are B → Wt/Zb/Hb. In the chiral limit with a branching ratio of 100% for the decay B → Wt, the observed (expected) 95% C.L. lower limit on the vectorlike B mass is 810 GeV (760 GeV). In the case where the vectorlike B quark has branching ratio values corresponding to those of an SU(2) singlet state, the observed (expected) 95% C.L. lower limit on the vectorlike B mass is 640 GeV (505 GeV). The same analysis, when used to investigate pair production of a colored, charge 5/3 exotic fermion T 5/3 , with subsequent decay T 5/3 → Wt, sets an observed (expected) 95% C.L. lower limit on the T 5/3 mass of 840 GeV (780 GeV)

Nanocrystalline silicon optomechanical cavities

"© 2018 Optical Society of America. One print or electronic copy may be made for personal use only. Systematic reproduction and distribution, duplication of any material in this paper for a fee or for commercial purposes, or modifications of the content of this paper are prohibited"[EN] Silicon on insulator photonics has offered a versatile platform for the recent development of integrated optomechanical circuits. However, there are some constraints such as the high cost of the wafers and limitation to a single physical device level. In the present work we investigate nanocrystalline silicon as an alternative material for optomechanical devices. In particular we demonstrate that optomechanical crystal cavities fabricated of nanocrystalline silicon have optical and mechanical properties enabling non-linear dynamical behaviour and effects such as thermo-optic/free-carrier-dispersion self-pulsing, phonon lasing and chaos, all at low input laser power and with typical frequencies as high as 0.3 GHz. (C) 2018 Optical Society of America under the terms of the OSA Open Access Publishing AgreementEuropean Commission project PHENOMEN (H2020-EU-713450), MINECO Severo Ochoa Excellence program (SEV-2013-0295), MINECO (FIS2015-70862-P, RYC-2014-15392) and CERCA Programme/Generalitat de Catalunya.Navarro-Urrios, D.; Capuj, N.; Maire, J.; Colombano, M.; Jaramillo-Fernandez, J.; Chavez-Angel, E.; Martín-Rodríguez, LL.... (2018). Nanocrystalline silicon optomechanical cavities. Optics Express. 26(8):9829-9839. https://doi.org/10.1364/OE.26.009829S98299839268Kippenberg, T. J., & Vahala, K. J. (2008). Cavity Optomechanics: Back-Action at the Mesoscale. Science, 321(5893), 1172-1176. doi:10.1126/science.1156032Aspelmeyer, M., Kippenberg, T. J., & Marquardt, F. (2014). Cavity optomechanics. Reviews of Modern Physics, 86(4), 1391-1452. doi:10.1103/revmodphys.86.1391Navarro-Urrios, D., Capuj, N. E., Gomis-Bresco, J., Alzina, F., Pitanti, A., Griol, A., … Sotomayor Torres, C. M. (2015). A self-stabilized coherent phonon source driven by optical forces. Scientific Reports, 5(1). doi:10.1038/srep15733Navarro-Urrios, D., Capuj, N. E., Colombano, M. F., García, P. D., Sledzinska, M., Alzina, F., … Sotomayor-Torres, C. M. (2017). Nonlinear dynamics and chaos in an optomechanical beam. Nature Communications, 8(1). doi:10.1038/ncomms14965Leijssen, R., La Gala, G. R., Freisem, L., Muhonen, J. T., & Verhagen, E. (2017). Nonlinear cavity optomechanics with nanomechanical thermal fluctuations. Nature Communications, 8(1). doi:10.1038/ncomms16024Gil-Santos, E., Labousse, M., Baker, C., Goetschy, A., Hease, W., Gomez, C., … Favero, I. (2017). Light-Mediated Cascaded Locking of Multiple Nano-Optomechanical Oscillators. Physical Review Letters, 118(6). doi:10.1103/physrevlett.118.063605Shah, S. Y., Zhang, M., Rand, R., & Lipson, M. (2015). Master-Slave Locking of Optomechanical Oscillators over a Long Distance. Physical Review Letters, 114(11). doi:10.1103/physrevlett.114.113602Weis, S., Rivière, R., Deléglise, S., Gavartin, E., Arcizet, O., Schliesser, A., & Kippenberg, T. J. (2010). Optomechanically Induced Transparency. Science, 330(6010), 1520-1523. doi:10.1126/science.1195596Verhagen, E., Deléglise, S., Weis, S., Schliesser, A., & Kippenberg, T. J. (2012). Quantum-coherent coupling of a mechanical oscillator to an optical cavity mode. Nature, 482(7383), 63-67. doi:10.1038/nature10787Tomes, M., & Carmon, T. (2009). Photonic Micro-Electromechanical Systems Vibrating atX-band (11-GHz) Rates. Physical Review Letters, 102(11). doi:10.1103/physrevlett.102.113601Thompson, J. D., Zwickl, B. M., Jayich, A. M., Marquardt, F., Girvin, S. M., & Harris, J. G. E. (2008). Strong dispersive coupling of a high-finesse cavity to a micromechanical membrane. Nature, 452(7183), 72-75. doi:10.1038/nature06715Eichenfield, M., Chan, J., Camacho, R. M., Vahala, K. J., & Painter, O. (2009). Optomechanical crystals. Nature, 462(7269), 78-82. doi:10.1038/nature08524Chan, J., Alegre, T. P. M., Safavi-Naeini, A. H., Hill, J. T., Krause, A., Gröblacher, S., … Painter, O. (2011). Laser cooling of a nanomechanical oscillator into its quantum ground state. Nature, 478(7367), 89-92. doi:10.1038/nature10461Safavi-Naeini, A. H., Alegre, T. P. M., Chan, J., Eichenfield, M., Winger, M., Lin, Q., … Painter, O. (2011). Electromagnetically induced transparency and slow light with optomechanics. Nature, 472(7341), 69-73. doi:10.1038/nature09933Pennec, Y., Laude, V., Papanikolaou, N., Djafari-Rouhani, B., Oudich, M., El Jallal, S., … Martínez, A. (2014). Modeling light-sound interaction in nanoscale cavities and waveguides. Nanophotonics, 3(6), 413-440. doi:10.1515/nanoph-2014-0004Davanço, M., Ates, S., Liu, Y., & Srinivasan, K. (2014). Si3N4 optomechanical crystals in the resolved-sideband regime. Applied Physics Letters, 104(4), 041101. doi:10.1063/1.4858975Balram, K. C., Davanço, M. I., Song, J. D., & Srinivasan, K. (2016). Coherent coupling between radiofrequency, optical and acoustic waves in piezo-optomechanical circuits. Nature Photonics, 10(5), 346-352. doi:10.1038/nphoton.2016.46Bochmann, J., Vainsencher, A., Awschalom, D. D., & Cleland, A. N. (2013). Nanomechanical coupling between microwave and optical photons. Nature Physics, 9(11), 712-716. doi:10.1038/nphys2748Xiong, C., Pernice, W. H. P., Sun, X., Schuck, C., Fong, K. Y., & Tang, H. X. (2012). Aluminum nitride as a new material for chip-scale optomechanics and nonlinear optics. New Journal of Physics, 14(9), 095014. doi:10.1088/1367-2630/14/9/095014Gomis-Bresco, J., Navarro-Urrios, D., Oudich, M., El-Jallal, S., Griol, A., Puerto, D., … Torres, C. M. S. (2014). A one-dimensional optomechanical crystal with a complete phononic band gap. Nature Communications, 5(1). doi:10.1038/ncomms5452Heck, M. J. R., Bauters, J. F., Davenport, M. L., Spencer, D. T., & Bowers, J. E. (2014). Ultra-low loss waveguide platform and its integration with silicon photonics. Laser & Photonics Reviews, 8(5), 667-686. doi:10.1002/lpor.201300183Solehmainen, K., Aalto, T., Dekker, J., Kapulainen, M., Harjanne, M., Kukli, K., … Leskela, M. (2005). Dry-etched silicon-on-insulator waveguides with low propagation and fiber-coupling losses. Journal of Lightwave Technology, 23(11), 3875-3880. doi:10.1109/jlt.2005.857750Sekoguchi, H., Takahashi, Y., Asano, T., & Noda, S. (2014). Photonic crystal nanocavity with a Q-factor of ~9 million. Optics Express, 22(1), 916. doi:10.1364/oe.22.000916Almeida, V. R., Barrios, C. A., Panepucci, R. R., & Lipson, M. (2004). All-optical control of light on a silicon chip. Nature, 431(7012), 1081-1084. doi:10.1038/nature02921Narayanan, K., & Preble, S. F. (2010). Optical nonlinearities in hydrogenated-amorphous silicon waveguides. Optics Express, 18(9), 8998. doi:10.1364/oe.18.008998Preston, K., Dong, P., Schmidt, B., & Lipson, M. (2008). High-speed all-optical modulation using polycrystalline silicon microring resonators. Applied Physics Letters, 92(15), 151104. doi:10.1063/1.2908869Wang, K.-Y., & Foster, A. C. (2012). Ultralow power continuous-wave frequency conversion in hydrogenated amorphous silicon waveguides. Optics Letters, 37(8), 1331. doi:10.1364/ol.37.001331Matres, J., Ballesteros, G. C., Gautier, P., Fédéli, J.-M., Martí, J., & Oton, C. J. (2013). High nonlinear figure-of-merit amorphous silicon waveguides. Optics Express, 21(4), 3932. doi:10.1364/oe.21.003932Waldow, M., Plötzing, T., Gottheil, M., Först, M., Bolten, J., Wahlbrink, T., & Kurz, H. (2008). 25ps all-optical switching in oxygen implanted silicon-on-insulator microring resonator. Optics Express, 16(11), 7693. doi:10.1364/oe.16.007693Wang, K.-Y., Petrillo, K. G., Foster, M. A., & Foster, A. C. (2012). Ultralow-power all-optical processing of high-speed data signals in deposited silicon waveguides. Optics Express, 20(22), 24600. doi:10.1364/oe.20.024600Ylönen, M., Torkkeli, A., & Kattelus, H. (2003). In situ boron-doped LPCVD polysilicon with low tensile stress for MEMS applications. Sensors and Actuators A: Physical, 109(1-2), 79-87. doi:10.1016/j.sna.2003.09.017Theodorakos, I., Zergioti, I., Vamvakas, V., Tsoukalas, D., & Raptis, Y. S. (2014). Picosecond and nanosecond laser annealing and simulation of amorphous silicon thin films for solar cell applications. Journal of Applied Physics, 115(4), 043108. doi:10.1063/1.4863402Navarro-Urrios, D., Gomis-Bresco, J., El-Jallal, S., Oudich, M., Pitanti, A., Capuj, N., … Sotomayor Torres, C. M. (2014). Dynamical back-action at 5.5 GHz in a corrugated optomechanical beam. AIP Advances, 4(12), 124601. doi:10.1063/1.4902171Barclay, P. E., Srinivasan, K., & Painter, O. (2005). Nonlinear response of silicon photonic crystal micresonators excited via an integrated waveguide and fiber taper. Optics Express, 13(3), 801. doi:10.1364/opex.13.000801Cuffe, J., Ristow, O., Chávez, E., Shchepetov, A., Chapuis, P.-O., Alzina, F., … Sotomayor Torres, C. M. (2013). Lifetimes of Confined Acoustic Phonons in Ultrathin Silicon Membranes. Physical Review Letters, 110(9). doi:10.1103/physrevlett.110.095503Volklein, F., & Balles, H. (1992). A Microstructure For Measurement Of Thermal Conductivity Of Polysilicon Thin Films. Journal of Microelectromechanical Systems, 1(4), 193-196. doi:10.1109/jmems.1992.752511Pennec, Y., Rouhani, B. D., El Boudouti, E. H., Li, C., El Hassouani, Y., Vasseur, J. O., … Martinez, A. (2010). Simultaneous existence of phononic and photonic band gaps in periodic crystal slabs. Optics Express, 18(13), 14301. doi:10.1364/oe.18.014301Escalante, J. M., Martínez, A., & Laude, V. (2014). Design of single-mode waveguides for enhanced light-sound interaction in honeycomb-lattice silicon slabs. Journal of Applied Physics, 115(6), 064302. doi:10.1063/1.486466

A search for prompt lepton-jets in pp collisions at root s=8 TeV with the ATLAS detector

A search is presented for a new, light boson with a mass of about 1 GeV and decaying promptly to jets of collimated electrons and/or muons (lepton-jets). The analysis is performed with 20.3 fb−1 of data collected by the ATLAS detector at the Large Hadron Collider in proton-proton collisions at a centre-of-mass energy of 8 TeV. Events are required to contain at least two lepton-jets. This study finds no statistically significant deviation from predictions of the Standard Model and places 95% confidence-level upper limits on the contribution of new phenomena beyond the SM, incuding SUSY-portal and Higgs-portal models, on the number of events with lepton-jets.We acknowledge the support of ANPCyT, Argentina; YerPhI, Armenia; ARC, Australia; BMWFW and FWF, Austria; ANAS, Azerbaijan; SSTC, Belarus; CNPq and FAPESP, Brazil; NSERC, NRC and CFI, Canada; CERN; CONICYT, Chile; CAS, MOST and NSFC, China; COLCIENCIAS, Colombia; MSMT CR, MPO CR and VSC CR, Czech Republic; DNRF, DNSRC and Lundbeck Foundation, Denmark; IN2P3-CNRS, CEADSM/IRFU, France; GNSF, Georgia; BMBF, HGF, and MPG, Germany; GSRT, Greece; RGC, Hong Kong SAR, China; ISF, I-CORE and Benoziyo Center, Israel; INFN, Italy; MEXT and JSPS, Japan; CNRST, Morocco; FOM and NWO, Netherlands; RCN, Norway; MNiSW and NCN, Poland; FCT, Portugal; MNE/IFA, Romania; MES of Russia and NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS and MIZ. S, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC and Wallenberg Foundation, Sweden; SERI, SNSF and Cantons of Bern and Geneva, Switzerland; MOST, Taiwan; TAEK, Turkey; STFC, United Kingdom; DOE and NSF, United States of America. In addition, individual groups and members have received support from BCKDF, the Canada Council, CANARIE, CRC, Compute Canada, FQRNT, and the Ontario Innovation Trust, Canada; EPLANET, ERC, FP7, Horizon 2020 and Marie Sklodowska-Curie Actions, European Union; Investissements d'Avenir Labex and Idex, ANR, Region Auvergne and Fondation Partager le Savoir, France; DFG and AvH Foundation, Germany; Herakleitos, Thales and Aristeia programmes co-financed by EU-ESF and the Greek NSRF; BSF, GIF and Minerva, Israel; BRF, Norway; the Royal Society and Leverhulme Trust, United Kingdom

Measurement of jet charge in dijet events from √s = 8 TeV pp collisions with the ATLAS detector

The momentum-weighted sum of the charges of tracks associated to a jet is sensitive to the charge of the initiating quark or gluon. This paper presents a measurement of the distribution of momentum-weighted sums, called jet charge, in dijet events using 20.3 fb−¹ of data recorded with the ATLAS detector at √s = 8 TeV in pp collisions at the LHC. The jet charge distribution is unfolded to remove distortions from detector effects and the resulting particle-level distribution is compared with several models. The pT dependence of the jet charge distribution average and standard deviation are compared to predictions obtained with several leading-order and next-to-leading-order parton distribution functions. The data are also compared to different Monte Carlo simulations of QCD dijet production using various settings of the free parameters within these models. The chosen value of the strong coupling constant used to calculate gluon radiation is found to have a significant impact on the predicted jet charge. There is evidence for a pT dependence of the jet charge distribution for a given jet flavor. In agreement with perturbative QCD predictions, the data show that the average jet charge of quark-initiated jets decreases in magnitude as the energy of the jet increases